BiopharmX vs Neothetics vs Galena

One of the most +++ biotech hot stocks +++ in 2017.

Who will make the run until 2040?

BiopharmX?

In Love, Temesta and friends  

BioPharmX is going to need to put the drug through (what will likely have to be) two phase III studies before it gets a chance at a commercialization green light, and that’s both costly and fraught with potential setbacks.  

:-)

Power on!  

BiopharmX and Galena on 2nd place +/-  

 

http://www.postanalyst.com/2017/04/12/...ce-of-3-hedge-fund-managers/  

1. Neo

2. Bio

3. Gal

Whatch out this week  

Sry  

 

Based on the timing of the study completion, the company now plans to announce topline data from the trial in the first half of May (!)

 

and nice weekend @ll  

Next level?  

Nice turn this week and top performance this month,

open your eyes,

Temesta and friends

 

https://ih.advfn.com/p.php?pid=nmona&article=74564127  

Q1-Bericht von Galena:
investors.galenabiopharma.com/investors/press-releases/press-rele­ase-details/2017/Galena-Biopharma-Reports-First-Quarter-2017-Fina­ncial-Results/default.aspx

Ich sehe ihn als Positiv  

;-)  

 

Wer ist mit an Bord?  

http://biopharmx.investorroom.com/...ignificance-for-Primary-Endpoint  

 

 

 

 

sieht gut aus